OncoMatch/Clinical Trials/NCT06002659
CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)
Is NCT06002659 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including CAR20(NAP)-T and Cyclophosphamide for b-cell lymphoma.
Treatment: CAR20(NAP)-T · Cyclophosphamide · Fludarabine — The purpose is to study the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of CAR20(NAP)-T for patients with B-cell malignancies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: MS4A1 overexpression (CD20+)
Relapsed or refractory CD20+ diffuse large B-cell lymphoma, mantle cell lymphoma or indolent lymphoma
Allowed: CD19 negative
Relapsed or refractory CD20+ B-cell lymphoma who are CD19 negative
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received:
The patient should have been treated with at least two lines of therapy and have no curative treatment option
Cannot have received: CD19-directed CAR T cell treatment
Exception: not eligible to receive clinically approved CD19-directed CAR T cell treatment
Relapsed or refractory CD20+ B-cell lymphoma that are not eligible to receive clinically approved CD19-directed CAR T cell treatment
Lab requirements
Blood counts
ANC ≥ 1x10^9/L; Platelet ≥ 50x10^9/L; Absolute lymphocyte count ≥ 0.1x10^9/L
Kidney function
Creatinine clearance (Cockcroft Gault) ≥ 30 mL/min
Liver function
ALT/AST ≤ 2.5x ULN; S-Bilirubin <1.5x ULN
Cardiac function
Cardiac ejection fraction ≥ 40%
Adequate bone marrow function as evidenced by: Absolute neutrophil count (ANC) ≥ 1x10^9/l/L; Platelet ≥ 50x 10^9/l; Absolute lymphocyte count ≥ 0,1x10^9/L. Adequate renal, hepatic, cardiac, and pulmonary function as evidenced by: Creatinine clearance (Cockcroft Gault) ≥ 30 mL/min; Serum Alanine aminotransferase/Aspartate aminotransferase (ALT/AST) ≤ 2.5 Upper limit of normal (ULN) and S-Bilirubin <1.5x UNL; Cardiac ejection fraction ≥ 40%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify